- Conditions
- Triple Negative Breast Cancer, HER2-negative Breast Cancer, Non Small Cell Lung Cancer, Cervical Cancer, Castrate Resistant Prostate Cancer, Pancreatic Ductal Adenocarcinoma, Head-and-neck Squamous Cell Carcinoma, Endometrial Cancer, Ovarian Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, Urothelial Carcinoma
- Interventions
- DR-0202
- Drug
- Lead sponsor
- Dren Bio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 10
- States / cities
- Denver, Colorado • Orlando, Florida • Sarasota, Florida + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 817–840
of 2,553
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Atrial Fibrillation
- Interventions
- AtriCure Bipolar System
- Device
- Lead sponsor
- AtriCure, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 9
- States / cities
- Sacramento, California • Indianapolis, Indiana • Grand Rapids, Michigan + 5 more
- Conditions
- Diabetes Mellitus, Diabetic Nephropathy
- Interventions
- FG-3019
- Drug
- Lead sponsor
- Kyntra Bio
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Tempe, Arizona • La Mesa, California + 15 more
- Conditions
- Fabry Disease
- Interventions
- Pegunigalsidase alfa
- Biological
- Lead sponsor
- Protalix
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Atlanta, Georgia • Iowa City, Iowa + 4 more
- Conditions
- Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET Gene Mutation, Metastatic Solid Tumor, Advanced Solid Tumor
- Interventions
- TPX-0046
- Drug
- Lead sponsor
- Turning Point Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 20
- States / cities
- La Jolla, California • Orange, California • Aurora, Colorado + 15 more
- Conditions
- KRAS-mutant Non-small Cell Lung Cancer (NSCLC), KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC), KRAS-mutant Colorectal Cancer (CRC), Other KRAS-mutant Solid Tumors
- Interventions
- KST-6051, Gemcitabine/nab-paclitaxel, Cetuximab, Pembrolizumab, mFOLFOX6, FOLFIRI, Pemetrexed, Carboplatin
- Drug
- Lead sponsor
- Kestrel Therapeutics, Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 545 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Sarasota, Florida • Tampa, Florida + 6 more
- Conditions
- Atrial Fibrillation
- Interventions
- Catheter Ablation
- Device
- Lead sponsor
- Volta Medical
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Jonesboro, Arkansas • Jacksonville, Florida + 11 more
- Conditions
- Relapsing-remitting Multiple Sclerosis
- Interventions
- Rebif®, Copaxone®
- Drug
- Lead sponsor
- EMD Serono
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 764 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 36 more
- Conditions
- Asthma
- Interventions
- QGE031
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 76 Years
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 5
- States / cities
- Evansville, Indiana • Owensboro, Kentucky • Waldorf, Maryland + 2 more
- Conditions
- Leukemia
- Interventions
- aldesleukin
- Biological
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2005
- U.S. locations
- 104
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 77 more
- Conditions
- Advanced Lung Cancer
- Interventions
- BNT324, BNT327
- Biological
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 594 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 13 more
- Conditions
- Extensive-stage Small-cell Lung Cancer
- Interventions
- Pumitamig, Atezolizumab, Etoposide, Carboplatin (or cisplatin if carboplatin is not tolerated)
- Drug
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 621 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 36
- States / cities
- Tucson, Arizona • Clermont, Florida • Palm Bay, Florida + 29 more
- Conditions
- SST2-positive Neuroendocrine Neoplasms, Neuroendocrine Tumors, Neuroendocrine Neoplasm
- Interventions
- CRN09682
- Drug
- Lead sponsor
- Crinetics Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Duarte, California • Newport Beach, California + 19 more
- Conditions
- Atrioventricular Block, Heart Diseases
- Interventions
- Cardiac Resynchronization Therapy (CRT)
- Device
- Lead sponsor
- Medtronic Cardiac Rhythm and Heart Failure
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 918 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2013
- U.S. locations
- 51
- States / cities
- Anchorage, Alaska • Peoria, Arizona • Little Rock, Arkansas + 48 more
- Conditions
- Alzheimer Disease
- Interventions
- AR1001, Placebo
- Drug
- Lead sponsor
- AriBio Co., Ltd.
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 1,535 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 75
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 62 more
- Conditions
- Non-Small Cell Lung Cancer, NSCLC, Adenocarcinoma, Heregulin
- Interventions
- MM-121, Docetaxel
- Drug
- Lead sponsor
- Elevation Oncology
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 17
- States / cities
- Tucson, Arizona • Los Angeles, California • Santa Rosa, California + 12 more
- Conditions
- Stage IA Breast Cancer, Stage IIA Breast Cancer
- Interventions
- Intraoperative Radiation Therapy, Laboratory Biomarker Analysis
- Radiation · Other
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 45 Years and older · Female only
- Enrollment
- 1,259 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2028
- U.S. locations
- 25
- States / cities
- Berkeley, California • Irvine, California • Los Angeles, California + 20 more
- Conditions
- Advanced or Metastatic Solid Tumor
- Interventions
- PLN-101095, Pembrolizumab
- Drug
- Lead sponsor
- Pliant Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 16
- States / cities
- New Haven, Connecticut • Atlanta, Georgia • Grand Rapids, Michigan + 11 more
- Conditions
- Fabry Disease
- Interventions
- 4D-310
- Biological
- Lead sponsor
- 4D Molecular Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 4
- States / cities
- La Jolla, California • Atlanta, Georgia • Pittsburgh, Pennsylvania + 1 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Rilvegostomig, Pembrolizumab, Carboplatin, Paclitaxel, Nab-paclitaxel
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 77
- States / cities
- Tucson, Arizona • Springdale, Arkansas • Anaheim, California + 69 more
- Conditions
- Non-Small-Cell Lung Carcinoma, Carcinoma, Non-Small Cell Lung
- Interventions
- Entinostat, Placebo, Erlotinib
- Drug
- Lead sponsor
- Syndax Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 141 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 30
- States / cities
- Tucson, Arizona • Denver, Colorado • Miami, Florida + 26 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Capmatinib, Amivantamab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Cerritos, California • Los Angeles, California + 2 more
- Conditions
- Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor, Head and Neck Squamous Cell Carcinoma HNSCC, HPV-associated Cancers, Neoadjuvant Melanoma, Neoadjuvant Cutaneous Squamous Cell Carcinoma (cSCC)
- Interventions
- TransCon TLR7/8 Agonist, Pembrolizumab
- Drug
- Lead sponsor
- Ascendis Pharma Oncology Division A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 17
- States / cities
- Duarte, California • Los Angeles, California • Orange, California + 13 more
- Conditions
- ALK+ Advanced NSCLC
- Interventions
- Brigatinib, Alectinib
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 248 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 4
- States / cities
- Whittier, California • Athens, Georgia • Albany, New York + 1 more